A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology

DOI10.1080/03610918.2019.1704784zbMath1489.62360OpenAlexW2998657885WikidataQ126526357 ScholiaQ126526357MaRDI QIDQ5866135

Shinjo Yada

Publication date: 13 June 2022

Published in: Communications in Statistics - Simulation and Computation (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/03610918.2019.1704784

zbMATH Keywords

adaptive designdrug combinationlate-onset outcomesphase I/II randomized trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Unnamed Item
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• A Bayesian dose-finding design for drug combination trials with delayed toxicities
• A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
• Bayesian survival analysis

This page was built for publication: A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology